DXCM 10-K Annual Reports

DexCom, Inc. (DXCM) reported a strong fiscal year 2025, with revenue reaching $4.66 billion, a 16% increase year-over-year. This growth was primarily driven by increased sales volume of their continuous glucose monitoring (CGM) systems, particularly the Dexcom G7 and the recently launched G7 15 Day system. The company added approximately 600,000-700,000 net customers in 2025. Despite increased sales, gross profit margin saw a slight decrease due to supply availability inefficiencies and build configuration impacts. However, operating income grew significantly by 52%, reaching $911.8 million, supported by controlled operating expenses and a substantial increase in other income. Net income also saw robust growth, up 45% to $836.3 million. The company ended the year with a strong liquidity position, holding $2.00 billion in cash, cash equivalents, and marketable securities, demonstrating effective financial management amidst product innovation and market expansion. The company continues to focus on product development and market expansion, with the recent launch of the Stelo biosensor for prediabetes and Type 2 diabetes patients who do not use insulin marking a strategic move to broaden their market reach. Dexcom is also actively managing regulatory landscapes, addressing an FDA warning letter received in March 2025 regarding manufacturing process non-conformities, and has submitted responses. The company is well-positioned for continued growth, driven by its innovative product pipeline and expanding global presence, though it faces ongoing competitive pressures and evolving reimbursement policies.

DexCom, Inc. (DXCM) has demonstrated robust performance in its latest annual report, driven by strong growth in its continuous glucose monitoring (CGM) systems. The company reported significant revenue growth, primarily fueled by increased sales volumes of its disposable sensors, indicating a growing global customer base. This expansion was supported by the launch of its Stelo biosensor in August 2024, targeting the prediabetes and Type 2 diabetes non-insulin user market, marking an entry into the over-the-counter space. Despite increased cost of sales due to higher volume and freight costs, the company managed to grow its gross profit, though gross profit margin saw a slight decrease. Overall, Dexcom maintained operating income and saw a notable increase in operating cash flow, reflecting effective operational management and continued demand for its innovative diabetes management solutions.

DexCom, Inc. (DXCM) reported strong revenue growth of 24% year-over-year, reaching $3.62 billion for the fiscal year ended December 31, 2023. This growth was primarily driven by increased sales volumes of their disposable continuous glucose monitoring (CGM) sensors, reflecting continued expansion of their global customer base. The company achieved significant improvements in profitability, with operating income up 53% and net income up 59% compared to the previous year. Dexcom's latest generation products, the G6 and G7 CGM systems, continue to drive adoption. The G7, launched in late 2022, offers key improvements such as a smaller profile, faster warm-up time, and enhanced features, further solidifying Dexcom's position in the diabetes management market. The company also noted ongoing progress in expanding its manufacturing capabilities and is actively pursuing strategic partnerships to broaden market access and enhance product offerings. Despite facing ongoing patent litigation with Abbott and various market risks, Dexcom's financial performance and strategic initiatives indicate a strong outlook for continued growth in the diabetes technology sector.

DexCom, Inc. (DXCM) reported strong performance in its 2022 10-K filing, highlighting significant revenue growth driven by increased sales volume of its disposable sensors. The company launched its latest generation continuous glucose monitoring (CGM) system, the Dexcom G7®, in December 2022, following FDA clearance, which is expected to further enhance its market position. Financially, Dexcom demonstrated robust growth with a 19% increase in revenue to $2.91 billion and a 57% rise in net income to $341.2 million. The company ended the year with a strong liquidity position, boasting $2.46 billion in cash, cash equivalents, and marketable securities. Dexcom continues to focus on product innovation, expanding market access, and strategic partnerships, particularly in the diabetes management ecosystem, positioning itself for continued growth in the expanding CGM market.

Dexcom, Inc. (DXCM), a leader in continuous glucose monitoring (CGM) systems, filed its 10-K on February 14, 2022, detailing its business and financial performance for the fiscal year ending December 31, 2021. The company reported robust revenue growth of 27%, reaching $2.45 billion, driven by increased sales volume of its disposable sensors. Gross profit also saw a significant increase of 31% to $1.68 billion, reflecting improved manufacturing efficiencies and economies of scale. Key strategic initiatives include the development and approval of its next-generation G7 CGM system, which promises enhanced features like reduced size and a fully disposable design. Dexcom continues to expand its partnerships with insulin delivery system manufacturers and broaden its market reach, including targeting Type 2 diabetes patients not on intensive insulin therapy. The company maintains a strong liquidity position with $2.73 billion in cash, cash equivalents, and marketable securities, positioning it well for continued investment in product innovation and market expansion.

DexCom, Inc. (DXCM) reported strong growth in its 2020 10-K filing, highlighting a 31% increase in total revenue, reaching $1.93 billion. This growth was primarily driven by increased sales volume of its disposable continuous glucose monitoring (CGM) sensors, reflecting continued expansion of its customer base globally. The company also saw an improvement in its gross profit margin to 66% from 63% in the prior year, attributed to higher revenues and manufacturing efficiencies. Operating expenses grew, with a significant portion dedicated to research and development to support next-generation products. The company continues to invest in product innovation, with the development of the Dexcom G7 system emphasizing reduced size, a fully disposable sensor and transmitter design, and faster warm-up times. Dexcom also benefits from strategic partnerships with insulin delivery companies, aiming to integrate its CGM technology into automated insulin delivery systems. The company's commercial strategy focuses on direct sales to healthcare professionals and expanding market access through distribution agreements and direct-to-consumer marketing. Despite challenges like pricing pressure and competition, Dexcom is well-positioned due to its technological leadership and growing market adoption.

DexCom Inc.'s 2020 10-K filing highlights a significant year of growth and product development, with a primary focus on their continuous glucose monitoring (CGM) systems, particularly the DexCom G6. The company has seen substantial revenue growth, driven by increased sales volume of disposable sensors, indicating expanding customer adoption of their technology. DexCom continues to invest heavily in research and development to enhance product performance and convenience, aiming to integrate their CGM technology with insulin delivery systems and expand their market reach to new patient populations and healthcare settings. Despite facing pricing pressures and ongoing competitive challenges, DexCom's strategic focus on technological advancement and market expansion positions it for continued growth in the diabetes management sector.

DexCom, Inc. (DXCM) reported strong revenue growth in its 2018 10-K filing, driven by the successful launch and adoption of its latest generation continuous glucose monitoring (CGM) system, the DexCom G6®. The company's focus remains on expanding its market leadership in diabetes management technology, with a clear strategy to innovate and broaden product indications. Key growth drivers include increased sales volume of disposable sensors and durable systems, supported by expanding direct sales efforts and strategic partnerships. Financially, while the company generated substantial revenue growth, it also incurred an operating loss, reflecting significant investments in research and development, sales, and marketing to fuel future expansion. The company's liquidity position appears robust, supported by substantial cash reserves and available credit facilities. Investors should monitor the company's continued investment in product development, market penetration, and the evolving reimbursement landscape for CGM technology.

DexCom, Inc. (DXCM) in its 2017 10-K filing, details its position as a leading medical device company focused on continuous glucose monitoring (CGM) systems for individuals with diabetes. The company highlights the development and commercialization of its G4 PLATINUM and G5 Mobile systems, emphasizing the G5 Mobile's "non-adjunctive" indication that allows for reduced fingerstick calibration, a significant advancement for diabetes management. Financially, DexCom reported significant revenue growth, driven by increased sales volume of disposable sensors and durable systems. However, the company also incurred operating losses, reflecting substantial investments in research and development, sales and marketing, and manufacturing capacity expansion. Key strategies include leveraging its technology platform, driving adoption through sales and partnerships, expanding market reach to Type 2 diabetes patients, and securing broad reimbursement coverage, particularly from Medicare. The company is also actively pursuing collaborations for data and insulin delivery integration. Significant risks identified include intense competition, reliance on third-party suppliers, regulatory hurdles and potential delays in product approvals, and the crucial aspect of securing consistent and adequate reimbursement from payors like Medicare and private insurers. The company is also investing in expanding its manufacturing capabilities, including a new facility in Mesa, Arizona, to meet anticipated demand.

DexCom, Inc. (DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. As of the February 28, 2017, 10-K filing, the company's primary products are the G4 PLATINUM and G5 Mobile CGM systems. The G5 Mobile system has achieved a significant milestone with a non-adjunctive indication from the FDA, allowing it to be used as a replacement for fingerstick testing for diabetes treatment decisions, though it still requires daily calibration. The company is focused on expanding its product offerings and market reach, including targeting Type 2 diabetes patients and exploring new applications. DexCom is also investing in research and development, including collaborations, to advance its technology platform and develop next-generation products. Despite a history of net losses, the company has seen significant revenue growth and is building out its sales and marketing infrastructure. Key strategic priorities include driving product adoption, seeking broad reimbursement coverage, expanding target demographics, and enhancing its cloud-based data platform. The company faces intense competition but aims to maintain its technological leadership.

DexCom Inc.'s 2016 10-K filing highlights its position as a leader in continuous glucose monitoring (CGM) systems for individuals with diabetes. The company has seen significant revenue growth, driven by its G4 PLATINUM and G5 Mobile systems, with increasing adoption of disposable sensors contributing to recurring revenue. DexCom is actively investing in research and development to enhance its product offerings and expand into new markets, including pediatric and in-hospital use. Despite strong revenue performance, DexCom continues to incur net losses, consistent with its early-stage growth phase and significant investment in innovation and market expansion. The company faces a competitive landscape but emphasizes its technological advancements, such as the G4 PLATINUM with Share and the G5 Mobile system, which offer enhanced connectivity and user convenience. Key to future success will be continued product innovation, regulatory approvals, market penetration, and securing favorable third-party reimbursement policies.

DexCom, Inc. (DXCM) is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management. In their 2014 10-K filing, the company highlights the significant progress made with their G4 PLATINUM system, including FDA approval for a pediatric indication and expanded professional use. The launch of the G4 PLATINUM with Share in early 2015 further enhances the product's appeal by enabling remote monitoring. The company is navigating a rapidly growing market driven by the increasing prevalence of diabetes and the recognized benefits of improved glycemic control through CGM. While revenue has grown substantially, DexCom continues to operate at a loss, investing heavily in research and development, sales, and marketing to expand its market reach and product pipeline. Key challenges include achieving broader third-party reimbursement, managing manufacturing scale-up, and competing with established players in the medical device industry. Despite these challenges, DexCom's focus on innovation and strategic partnerships positions it for continued growth in the diabetes technology sector.

DexCom, Inc. (DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems. The company's primary product, the G4 PLATINUM system, is designed for ambulatory use by individuals with diabetes, offering real-time glucose readings, trend information, and alerts. As of the February 20, 2014 filing, DexCom has received FDA approval for a pediatric indication for the G4 PLATINUM system, expanding its target market. The company is also developing an in-hospital glucose monitoring system, GlucoClear, and a remote monitoring system, DexCom SHARE. Despite significant revenue growth, driven by the G4 PLATINUM system's commercialization, DexCom continues to incur net losses, consistent with its history since inception. Key challenges include the ongoing need for reimbursement from third-party payors, the competitive landscape with established medical device manufacturers, and potential patent litigation with Abbott. The company's strategy focuses on technological innovation, expanding market access through direct sales and partnerships, and securing broad insurance coverage and reimbursement for its products.

DexCom, Inc. reported its 2012 annual results, highlighting significant progress in its continuous glucose monitoring (CGM) technology. The company received FDA approval for its fourth-generation G4 PLATINUM system in October 2012, a key advancement designed for improved accuracy, a sleeker receiver, and better sensor performance. This new system is poised to be a primary revenue driver, with marketing efforts shifting from the older SEVEN PLUS model. The company also expanded its reach by securing CE Mark approval for the G4 system in Europe and other international markets. Financially, DexCom saw a substantial increase in product revenue, reaching $93.0 million in 2012, driven by higher sales volumes and the introduction of the G4 PLATINUM. However, the company continued to incur net losses, with a reported net loss of $54.5 million for the year. Despite ongoing losses, the company's cash position remained stable, and it raised capital through equity offerings. The company is focused on further development, including seeking pediatric indications for its G4 PLATINUM system, and expanding market access through strategic partnerships and reimbursement efforts.

This filing is an amendment (No. 2) to DexCom Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. The document primarily consists of an extensive exhibit index detailing various agreements, plans, and incorporation by reference from previous filings. It confirms DexCom's status as a large accelerated filer and a non-shell company. Investors should note that the core financial statements and detailed business operations are not present in this specific amendment, which focuses on the exhibits and formal certifications. The filing's purpose is to provide a comprehensive list of supporting documents and confirm adherence to reporting requirements as of the filing date of May 15, 2012. Key details available within this amendment include the registration of common stock and preferred stock purchase rights on the NASDAQ Stock Market, the number of outstanding common shares as of March 26, 2012 (68,534,954), and the market value of non-affiliate shares as of June 30, 2011. The exhibit index reveals a history of significant agreements related to development, licensing, collaboration, and executive compensation, indicating active strategic partnerships and internal management structures.

This 10-K filing from Dexcom, Inc. (DXCM) for the fiscal year ended December 31, 2011, highlights the company's growth trajectory and its strategic focus on expanding product revenue while managing operating losses. The company reported a significant increase in product revenue, reaching approximately $65.9 million, a 64% jump from the previous year, demonstrating strong commercial performance and market adoption. Dexcom's executive compensation strategy for 2011 emphasized conserving cash by favoring equity-based incentives over cash salaries, aiming to align employee interests with long-term stockholder value and support the company's goal of achieving profitability. The filing also details the company's corporate governance structure, board of directors, and executive compensation policies, including details on base salaries, bonus plans, and equity awards, reflecting a pay-for-performance philosophy. The robust board composition, with a majority of independent directors, and the clear committee structures underscore a commitment to sound governance.

DexCom, Inc., in its 2011 10-K filing, reported significant revenue growth driven by its SEVEN PLUS continuous glucose monitoring system. The company is focused on expanding its product offerings and market reach, including development of in-hospital solutions and partnerships for insulin pump integration. Despite strong revenue increases, DexCom continued to incur net losses, underscoring the high R&D and SG&A expenses associated with its growth strategy and the medical device market. Key investor considerations include the company's progress in gaining market acceptance for continuous glucose monitoring, the importance of reimbursement from third-party payors, and the ongoing legal dispute with Abbott Diabetes Care. DexCom's future success hinges on its ability to navigate regulatory pathways, secure broader reimbursement, manage manufacturing scale-up, and continue product innovation in a competitive landscape.

DexCom, Inc. (DXCM) presented its 2010 Form 10-K filing, detailing its progress as a medical device company focused on continuous glucose monitoring (CGM) systems. The company's primary product, the SEVEN PLUS system, is designed for ambulatory use by individuals with diabetes and saw increased sales volume and average selling prices in 2010 compared to 2009. Despite revenue growth, DexCom continued to incur significant operating losses, consistent with its early commercialization stage, with a reported net loss of $55.17 million for the year. The company is actively investing in research and development for next-generation products and exploring the in-hospital market with its GlucoClear system. Key financial and operational highlights include a substantial increase in product revenue to $40.2 million, driven by higher sales of the SEVEN PLUS system. However, the company's operating expenses, particularly in selling, general, and administrative functions, also rose significantly. DexCom secured additional funding through follow-on public offerings, raising approximately $66 million in 2010 to support its ongoing commercialization and development efforts. The company is also navigating significant legal challenges, including a patent infringement lawsuit with Abbott Diabetes Care, which poses a notable risk. Despite the ongoing losses, DexCom is positioning itself for future growth by expanding its sales force and advancing its technology platform.

DexCom, Inc. (DXCM) in its 2010 10-K filing highlights its position as an emerging medical device company focused on continuous glucose monitoring (CGM) systems. The company has launched its third-generation product, the SEVEN PLUS, designed for up to seven days of use, and is also developing in-hospital monitoring solutions in partnership with Edwards Lifesciences. Despite product advancements and growing market potential due to increasing diabetes prevalence, DexCom faces significant risks. Key challenges include achieving broad market acceptance for its products, which are adjunctive to traditional blood glucose monitoring and may not be fully reimbursed by payors. The company has a limited operating history and has incurred substantial losses since inception, with expectations of continued losses in the foreseeable future. Furthermore, DexCom is embroiled in a significant patent infringement lawsuit with Abbott Diabetes Care, which poses a substantial financial and operational risk. Manufacturing capacity, supply chain reliance on single-source suppliers, and regulatory hurdles are also critical areas of concern for investors.

DexCom, Inc. (DXCM) in its March 5, 2009, 10-K filing, reveals a company in its early commercialization phase, focused on developing and selling continuous glucose monitoring (CGM) systems. The company has received FDA approval for its SEVEN and SEVEN PLUS systems, designed for up to seven days of use, and is working towards broader market acceptance. However, DexCom faces significant challenges including a limited operating history, the need for market acceptance by physicians and patients, potential manufacturing and supply chain issues, and the critical hurdle of securing adequate reimbursement from third-party payors, which is not yet broadly established. Financially, DexCom has incurred substantial net losses since inception, with a significant accumulated deficit. The company relies on ongoing financing, having recently completed a public stock offering. A major concern highlighted is the significant debt obligation from convertible senior notes, which could lead to dilution for existing shareholders upon conversion. Additionally, DexCom is embroiled in a patent infringement lawsuit with Abbott Diabetes Care, which poses a substantial risk to its business operations and financial stability.

DexCom, Inc. is a medical device company in the early stages of commercializing its continuous glucose monitoring (CGM) systems. The company received FDA approval for its SEVEN system in May 2007 and began commercialization in Q3 2007, with sales of this product expected to drive future revenue. Despite generating approximately $6.8 million in revenue through December 31, 2007, DexCom has incurred significant losses since inception, with an accumulated deficit of $176.3 million as of the same date. Key challenges and risks for investors include the need for broader market and physician acceptance of its products, potential manufacturing and supply chain constraints, the lack of widespread third-party reimbursement, and significant ongoing research and development expenses. The company is also facing a patent infringement lawsuit from Abbott Diabetes Care, Inc., which poses a material risk to its business. Furthermore, DexCom has a substantial debt burden with $60 million in convertible senior notes outstanding, and the potential conversion of these notes could dilute existing stockholders. While the company has a cash balance of $64.3 million as of December 31, 2007, it anticipates continued losses and may require additional funding to support its growth and product development initiatives.

DexCom, Inc. filed its 2006 Form 10-K on February 27, 2007, reporting on its early commercialization efforts for its Short-Term Continuous Glucose Monitoring System (STS®). The company received FDA approval for the STS in March 2006 and launched it shortly after. Despite commencing revenue generation, DexCom incurred a significant net loss of $46.6 million for the year, reflecting substantial investments in research and development, sales, marketing, and manufacturing infrastructure. The company is actively working to establish market acceptance, build its sales force, and secure reimbursement from third-party payors, which are critical for future revenue growth. DexCom also faces ongoing challenges including manufacturing scale-up, potential product failures, patent litigation with Abbott Diabetes Care, and the competitive landscape within the diabetes monitoring market.

This 10-K filing from DexCom, Inc. (DXCM) on February 27, 2006, details the company's progress in developing continuous glucose monitoring (CGM) systems. As a development-stage company, DexCom has not yet generated revenue but has invested heavily in research and development for both a short-term (3-day) and a long-term (up to 1-year) CGM system. The company has submitted a Premarket Approval (PMA) application for its short-term system to the FDA and is awaiting a decision. The report highlights the significant market opportunity in diabetes management and the limitations of existing finger-stick glucose monitoring methods, positioning DexCom's technology as a potential solution offering greater convenience and real-time data. The company faces substantial risks, including the uncertainty of FDA approval, intense competition from established medical device manufacturers, potential intellectual property disputes (including a lawsuit filed by Abbott Diabetes Care), and the need for significant future funding. DexCom's financial performance reflects its development stage, with substantial net losses incurred to date. The company's strategy focuses on establishing its technology as a leader in CGM, rapidly bringing products to market, maintaining high quality standards, and building a direct sales and marketing effort. The filing also provides detailed information on clinical trials, manufacturing capabilities, intellectual property, and regulatory challenges.